KJ Stepping into the Holidays After a Milestone Year
Dec 17, 2025
KJ is celebrating a big year after becoming the first patient in the world to receive a personalized CRISPR gene editing therapy to treat his rare disease.
Our team of attending physicians, genetic counselors, nurses and dietitians work with a variety of departments at CHOP to ensure a continuity of care and individualized treatment for children with genetic conditions.
Dec 17, 2025
KJ is celebrating a big year after becoming the first patient in the world to receive a personalized CRISPR gene editing therapy to treat his rare disease.
Nov 13, 2025
Children’s Hospital of Philadelphia (CHOP) announced that seven of its physicians and researchers were among the 92 new members selected to join the American Pediatric Society (APS), one of North America's first and most prestigious academic pediatric organizations.
Aug 19, 2025
Researchers found that a new drug therapy currently in clinical trials for a form of primary mitochondrial disease – Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) syndrome – was safe and effective in multiple preclinical zebrafish models.
May 15, 2025
Landmark study from CHOP and Penn Medicine showcases the power of customized gene editing therapy to treat patient with rare metabolic disease.
Apr 17, 2025
The methods help identify “footprints” that indicate binding sites and reveal variants that could increase risk for a variety of common diseases.
Feb 24, 2025
New techniques were utilized to recreate the goals of a natural history study of rare diseases in a fraction of the time.
Dec 12, 2024
MMFP-Tableau offers a readily generalizable solution to make research and clinical electronic health system data more accessible and impactful.
Oct 10, 2024
Researchers aim to develop personalized therapies for urea cycle disorders and other genetic conditions using advanced CRISPR technology.
Sep 27, 2024
Hundreds of variants in “secondary finding” genes could guide treatment for patients to avoid risks and complications of health issues in adulthood.
Sep 4, 2024
The ex vivo gene therapy improved sulfatase production and reduced symptoms associated with the disease in preclinical models